[Expression Wnt2 in breast cancer tissues and sera of the patients]

To observe the expression of Wnt2 in the breast cancer cells (MDA-MB-231, ZR-75-30 and MCF-7) and tissues, and analyze the correlation of Wnt2 expression with CA-153 in the sera of patients with breast cancer.

The expression of Wnt2 at both mRNA and protein levels was measured respectively by real-time fluorescent quantitative PCR and Western blotting in the three human breast cancer cell lines. In addition, the immunohistochemistry (IHC) was applied to detect the expression of Wnt2 in 5 corresponding tissues adjacent to cancer, 9 breast carcinoma in situ and 9 invasive breast cancer; ELISA was used to detect Wnt2 and electrochemiluminescence immunoassay was used to detect CA-153 in the sera of 15 normal women and 30 patients with breast cancer. Furthermore, we collected complete clinicopathological data from the participating subjects, and analyzed their relationships with serum Wnt2 levels.

The mRNA and protein of Wnt2 were negative in the three human breast cancer cells, while Wnt2 in the epithelial and interstitial cells of breast cancer tissues was significantly higher than that in normal tissues (P<0.05). The expression levels of Wnt2 and CA-153 in the sera of patients with breast cancer were higher than those in normal women (P<0.05), and Wnt2 levels in the sera of breast cancer patients were positively correlated with serum CA-153 levels.

Simultaneous tests of Wnt2 and CA-153 levels in the serum may help the diagnostic screening of breast cancer.